BR9607538A - Lactobacilos aderentes ao epitélio - Google Patents

Lactobacilos aderentes ao epitélio

Info

Publication number
BR9607538A
BR9607538A BR9607538A BR9607538A BR9607538A BR 9607538 A BR9607538 A BR 9607538A BR 9607538 A BR9607538 A BR 9607538A BR 9607538 A BR9607538 A BR 9607538A BR 9607538 A BR9607538 A BR 9607538A
Authority
BR
Brazil
Prior art keywords
pct
mannose
date sep
sec
strain
Prior art date
Application number
BR9607538A
Other languages
English (en)
Portuguese (pt)
Inventor
Ingegerd Adlerberth
Siv Ahrne
Bengt Jeppsson
Marie-Louise Johansson
Goran Molin
Agnes Wold
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Publication of BR9607538A publication Critical patent/BR9607538A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BR9607538A 1995-03-23 1996-03-25 Lactobacilos aderentes ao epitélio BR9607538A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501056A SE9501056D0 (sv) 1995-03-23 1995-03-23 Epithelial adherent lactobacilli
PCT/SE1996/000372 WO1996029083A1 (en) 1995-03-23 1996-03-25 Epithelial adhesive lactobacilli

Publications (1)

Publication Number Publication Date
BR9607538A true BR9607538A (pt) 1998-01-06

Family

ID=20397666

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607538A BR9607538A (pt) 1995-03-23 1996-03-25 Lactobacilos aderentes ao epitélio

Country Status (16)

Country Link
US (1) US6159465A (enExample)
EP (1) EP0817640B1 (enExample)
JP (1) JP4072646B2 (enExample)
KR (1) KR100446482B1 (enExample)
CN (1) CN1138551C (enExample)
AT (1) ATE240738T1 (enExample)
AU (1) AU702705B2 (enExample)
BR (1) BR9607538A (enExample)
CA (1) CA2216150C (enExample)
DE (1) DE69628288T2 (enExample)
EE (1) EE04097B1 (enExample)
ES (1) ES2200057T3 (enExample)
NO (1) NO974371L (enExample)
PL (1) PL184037B1 (enExample)
SE (1) SE9501056D0 (enExample)
WO (1) WO1996029083A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100376954B1 (ko) * 1995-07-31 2003-07-18 프로비 에이비 장에서집락화하는유산간균
DE69802413T3 (de) * 1997-07-05 2009-07-16 Société des Produits Nestlé S.A. LACTOBACILLI ZUR ERHöHUNG DER MINERALIENABSORPTION DURCH DARMZELLEN
FI974643A7 (fi) * 1997-12-30 1999-07-01 Suomen Rehu Oy Biologinen menetelmä salmonellan eliminoimiseksi prosesseista ja rakenteista
BR9914184A (pt) * 1998-10-01 2001-06-19 Probi Ab Redução de fatores de forças oxidativas
CA2378620A1 (en) * 1999-08-09 2001-02-15 Pinaki Panigrahi Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
DE60018591T2 (de) 1999-10-26 2006-04-13 Société des Produits Nestlé S.A. Milchsäurebakterien zur behandlung und prophylaxe von giardiasis
GB2369777B (en) * 2000-10-05 2004-10-27 St Ivel Ltd Food products with antimicrobial lactic acid bacteria
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use
FR2826020B1 (fr) * 2001-06-14 2005-02-11 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
FR2831555A1 (fr) * 2001-10-29 2003-05-02 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
RU2004100545A (ru) * 2001-06-14 2005-05-10 Сева Санте Анималь (Fr) Способ селекции непатогенных грамположительных штаммов молочнокислых бактерий
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
WO2005086870A2 (en) * 2004-03-10 2005-09-22 The Board Of Trustees Of The University Of Illinois Novel lactobacillus strains and method of use
DE602005020915D1 (de) * 2004-03-23 2010-06-10 Friesland Brands Bv Mannose-spezifische adhesinen und deren vervendung
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
JP2006180836A (ja) * 2004-12-28 2006-07-13 Marudai Food Co Ltd 食中毒菌感染を抑制する乳酸菌、ならびにそれを含む発酵物、食品および医薬組成物
JP2006257077A (ja) * 2005-02-18 2006-09-28 Marudai Food Co Ltd 免疫調節剤および免疫調節食品
CN1888051B (zh) * 2005-06-28 2010-05-05 北京天佑达生物工程科技有限公司 一株植物乳杆菌及其应用
SE529199C2 (sv) * 2005-07-05 2007-05-29 Probi Ab Förstärkt absorption
WO2007036230A1 (en) 2005-09-28 2007-04-05 Nordisk Rebalance A/S Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment effectors
AU2006325531B2 (en) 2005-12-13 2012-04-19 Exthera Medical Corporation Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
FR2928935B1 (fr) 2008-03-19 2011-05-20 Gervais Danone Sa Souche de lactobacillus rhamnosus.
EP2459203B1 (en) * 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Lactic acid bacteria and bifidobacteria for treating endotoxemia
CA2782311C (en) 2009-12-01 2017-06-27 Robert S. Ward Method for removing cytokines from blood with surface immobilized polysaccharides
AU2011209407B2 (en) 2010-01-28 2014-02-27 Ab-Biotics S.A. Probiotic composition for use in the treatment of bowel inflammation
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
BG66608B1 (bg) * 2011-05-04 2017-10-16 "Ел Би Булгарикум" ЕАД Полибактериален пробиотичен препарат
CN102618456B (zh) * 2012-02-28 2013-08-21 江南大学 一种能够缓解慢性酒精性肝损伤的鼠李糖乳杆菌及其用途
EP2861273B1 (en) 2012-06-13 2017-08-23 ExThera Medical Corporation Use of heparin and carbohydrates to treat cancer
JP2012184261A (ja) * 2012-06-21 2012-09-27 Snow Brand Milk Products Co Ltd 免疫増強剤
CN102827796B (zh) * 2012-09-03 2013-10-30 江南大学 一种具有排镉功能的植物乳杆菌及其用途
WO2014047625A1 (en) 2012-09-24 2014-03-27 Montana State University Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
EP3013445B1 (en) * 2013-06-24 2019-11-06 ExThera Medical Corporation Blood filtration system containing mannose coated substrate
MX382486B (es) 2013-11-08 2025-03-13 Exthera Medical Corp Métodos para diagnosticar enfermedades infecciosas usando medio de adsorción.
JP2017513636A (ja) 2014-04-24 2017-06-01 エクスセラ メディカル コーポレイション 高流量を用いて血液から細菌を除去するための方法
US10857283B2 (en) 2014-09-22 2020-12-08 Exthera Medical Corporation Wearable hemoperfusion device
WO2017058175A1 (en) 2015-09-29 2017-04-06 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
US10786615B2 (en) 2016-03-02 2020-09-29 Exthera Medical Corporation Method for treating drug intoxication
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
WO2018160158A1 (en) 2017-02-28 2018-09-07 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
WO2019103198A1 (ko) 2017-11-24 2019-05-31 주식회사 고바이오랩 락토바실러스 퍼멘텀 kbl 375 균주 및 그 용도
JP7121233B2 (ja) 2018-05-09 2022-08-18 コバイオラブズ・インコーポレイテッド ラクトバチルス・パラカゼイ株及びその使用
NZ770137A (en) 2018-05-23 2024-03-22 Ko Biolabs Inc Lactobacillus gasseri kbl697 strain and use thereof
JP2022534191A (ja) 2019-05-16 2022-07-28 エクスセラ メディカル コーポレイション 内皮糖衣構造を調節するための方法
EP3981255A4 (en) 2019-06-05 2023-01-25 Morinaga Milk Industry Co., Ltd. NUTRITIONAL COMPOSITION
CN111575223B (zh) * 2020-05-20 2022-04-15 江南大学 一种降低鼠李糖乳杆菌表面物质分泌量的方法
CN119242500A (zh) * 2024-09-30 2025-01-03 尚品健康科技(青岛)有限公司 一株母乳来源植物乳植杆菌改善过敏性疾病和调节肠道菌群的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203586A3 (en) * 1985-05-29 1988-03-09 Pioneer Hi-Bred International A composition for treating gastrointestinal disease in animals
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
GB9124249D0 (en) * 1991-11-14 1992-01-08 Goldstein Fredric Ribbon curling and shredding device
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection

Also Published As

Publication number Publication date
WO1996029083A1 (en) 1996-09-26
DE69628288D1 (de) 2003-06-26
CN1138551C (zh) 2004-02-18
CA2216150C (en) 2008-01-22
DE69628288T2 (de) 2004-04-08
EP0817640B1 (en) 2003-05-21
ATE240738T1 (de) 2003-06-15
HK1017989A1 (en) 1999-12-10
ES2200057T3 (es) 2004-03-01
AU5166596A (en) 1996-10-08
EE04097B1 (et) 2003-08-15
SE9501056D0 (sv) 1995-03-23
KR100446482B1 (ko) 2006-01-27
PL322550A1 (en) 1998-02-02
JP4072646B2 (ja) 2008-04-09
KR19980703102A (ko) 1998-10-15
JPH11502703A (ja) 1999-03-09
NO974371L (no) 1997-11-20
CN1185111A (zh) 1998-06-17
EE9700329A (et) 1998-06-15
EP0817640A1 (en) 1998-01-14
PL184037B1 (pl) 2002-08-30
AU702705B2 (en) 1999-03-04
US6159465A (en) 2000-12-12
NO974371D0 (no) 1997-09-22
CA2216150A1 (en) 1996-09-26

Similar Documents

Publication Publication Date Title
BR9607538A (pt) Lactobacilos aderentes ao epitélio
Chauvière et al. Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells
Coconnier et al. Inhibition of adhesion of enteroinvasive pathogens to human intestinal Caco-2 cells by Lactobacillus acidophilus strain LB decreases bacterial invasion
Gopal et al. In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli
Mayrand et al. Biological activities of outer membrane vesicles
Ogawa et al. Inhibition of Streptococcus mutans biofilm formation by Streptococcus salivarius FruA
Lamont et al. Subgingival colonization by Porphyromonas gingivalis
TR200101699T2 (tr) Urogenital enfeksiyonların önlenmesi ve tedavisi için ağızdan lactobakilus uygulaması
Li et al. Association of proteases of Porphyromonas (Bacteroides) gingivalis with its adhesion to Actinomyces viscosus
AU2613995A (en) Lactobacillus strains of human origin, their compositions and uses thereof
FR2808689B1 (fr) Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
Neilands et al. Parvimonas micra stimulates expression of gingipains from Porphyromonas gingivalis in multi-species communities
WO2004007695A3 (en) Lactobacilli expressing biologically active polypeptides and uses thereof
Michel et al. Isolation of an Acanthamoeba strain with intracellular Burkholderia pickettii infection
EE9700269A (et) Farmatseutiline kompositsioon, mis sisaldab Lactobacillus plantarum'it ja arginiini
WO2003039260A3 (en) PROBIOTIC COMPOSITIONS
Henriksson et al. Adhesion of Lactobacillus fermentum 104-S to porcine stomach mucus
Aleljung et al. Collagen binding by lactobacilli
DK0858501T3 (da) Mælkesyrebakteriepræparater samt deres anvendelse til fremstilling af kolesterolsænkende produkter
Iwamoto et al. The Japanese fermented food natto inhibits sucrose-dependent biofilm formation by cariogenic streptococci
Grenier Production of trypsin and chymotrypsin inhibitors by oral bacterial isolates
Hryniewicz et al. The first national external quality assessment scheme in clinical bacteriology in Poland(POLMicro I)
LeVatte Repression of the Pseudomonas aeruginosa ferripyochelin-binding protein expression by subinhibitory concentrations of antibiotics
HAYES Purification and Mode of Action of a Bacteriocin Produced by Bacteroides Fragilis
Fiuzat Study of Lactobacillus reuteri in vitro, in situ and in the gastrointestinal tract of CD-1 mice.

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal